Entities / Company
NJOY.
e-cigarette company based in Scottsdale, Arizona
- Reports this week
- 0
- Active events
- 2
- Connections
- 6
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
Gone quiet
No new reports in 90+ days-
Glas submitted data to the FDA for approval regarding NJOY flavored products, following previous FDA sanctions on NJOY.Well supported5 reports
-
Altria's smoke-free asset NJOY is underperforming.Some support2 reports1 development inside
-
Altria reduced the carrying value of its NJOY purchase, invested in Cronos, and lost a lawsuit against Juul.Speculative1 report
No events began in the chosen period. Widen it, or reset.
Around NJOY this week
News at the entities that move NJOY most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves NJOY
-
Altria StructuralPhilip Morris International and Altria operate in the tobacco industry, noting that IQOS is maturing in high-penetration markets like Europe.Moves NJOY
-
Food and Drug Administration StructuralIn 2007, CBS broadcast featured Andrews, Cordes, and Couric criticizing the Food and Drug Administration's problems.Moves NJOY
Connections
The 3 strongest of 6, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Altria Structural
Altria owns and operates the NJOY brand as a portfolio asset, managing its market presence and product lifecycle.
-
FDA Structural
The FDA formally regulates NJOY's e-cigarette products, setting market standards for their viability and operation.
-
Food and Drug Administration Structural
The FDA has previously sanctioned NJOY products under its regulatory authority.
History
Events by the month they beganJune 2026
5 events- FDA sets standards for e-cigarette product approval.
- Tightening regulations on tobacco sales were reported involving Altria and Marlboro.
- Glas submitted data to the FDA for approval regarding NJOY flavored products, following previous FDA sanctions on NJOY.
- Altria's smoke-free asset NJOY is underperforming.
- Altria reduced the carrying value of its NJOY purchase, invested in Cronos, and lost a lawsuit against Juul.